About Us

We address the underlying causes of ophthalmic diseases

Enhancing Lives & Better Vision

Okogen is an ophthalmic specialty pharmaceutical company focused on developing innovative therapies to treat adenoviral conjunctivitis.

We believe in addressing both the underlying cause of the disease and treating the associated symptoms. 

Our lead product candidate, OKG-0502, is being developed to treat adenoviral conjunctivitis (also known as pink eye), a viral infection that affects approximately 30 million people worldwide each year and for which there are no approved therapies.

Meet the Team

Meet the Team

Management

Joshua H. Moriarty

Chief Executive Officer

Joshua H Moriarty

Chief Executive Officer

Joshua H Moriarty is the Chief Executive Officer of Okogen, Inc. Joshua has spent 17 years in ophthalmic product development, most recently as Executive Director at Ora, Inc. working alongside small to mid-size ophthalmic companies traversing the development process.

Joshua received his Bachelor of Arts from the University of Massachusetts and is the proud father of 2 daughters.

Read More

Board of Directors

Brian M Strem, PhD

Brian M Strem, PhD

Brian M Strem, PhD is a co-founder of Okogen Inc and current President & CEO of Kiora Pharmaceuticals (NASDAQ:KPRX). Previously, Brian worked at Sound Pharmaceuticals, Allergan and Shire, responsible for business development and corporate strategy in ophthalmology, otology and regenerative medicine. Brian began his career at Cytori Therapeutics with elevating roles within the commercial and R&D departments.

Brian received his BS in bioengineering from Cornell University and his PhD in biomedical engineering from UCLA.

Read More

Eric Daniels, MD, MBA

Eric Daniels, MD, MBA

Eric Daniels, MD, MBA is a Co-Founder of Okogen and is currently the Chief Development Officer at Kiora Pharmaceuticals (NASDAQ:KPRX). Eric has nearly 20 years of operating experience in biotechnology and medtech companies, including Tensys Medical, Kerastem, and Cytori Therapeutics, where he has held leadership roles within the commercial, medical and R&D organizations.

Eric holds a Masters of Business Administration from the Anderson School of Management at the University of California, Los Angeles. He received his Doctor of Medicine degree from the University of California, Los Angeles School of Medicine and his undergraduate degree in Molecular Biology from the University of California, Berkeley.

Read More

Chris Smith, PhD, MBA

Chris Smith

Chris Smith, PhD, MBA is a Senior Investment Manager at Brandon Capital Partners, Australia’s largest life-science VC. Before this Chris was a Business Development Manager with CSL Ltd, Australia’s largest pharmaceutical company and one of the top 10 biotechnology companies in the world. At CSL Chris was responsible for identifying and reviewing opportunities for CSL’s global R&D pipeline. Chris spent three years as a postdoctoral immunologist and virologist at The University of Cambridge, UK.

Read More

Leighton Read, MD

Leighton Read

Leighton Read, MD is a serial entrepreneur and venture investor with a long track record of building companies that have commercialized important medicines and life-science technologies. From 2000 – 2008 he was a managing director of Alloy Ventures, an early-stage firm investing in life science and technology companies.

Previously, he founded Affymax NV (sold to GSK) and spun out Affymetrix and Maxygen. He was the founding investor, Chairman and CEO of Aviron which developed FluMist™, the intranasal influenza vaccine (acquired by MedImmune). Leighton serves as a trustee or director of The BeneTech Initiative, BioVentures for Global Health, The UC Berkeley Foundation and School of Public Health Council, and is Vice Chairman of the Santa Fe Institute.

Read More

Quinton Oswald

Quinton Oswald

Quinton Oswald was the CEO of Notal Vision, a cloud based telemedicine company driven by AI tools. Prior to that, he served as CEO of Neurotech Pharmaceuticals and SARcode Bioscience, where he was instrumental in the clinical development of lifitegrast ophthalmic solution 5% (Xiidra™) for the treatment of dry eye disease (sold to Shire, PLC).

Previously, he served as the Vice President & Business Unit Head for Genentech’s Tissue Growth and Repair Business, where he also oversaw the  commercial launch of Lucentis® (ranibizumab) for the treatment of wet AMD. Prior to Genentech, Quinton led the North American Ophthalmology business for Novartis, which, in conjunction with QLT, Inc., pioneered Visudyne® (verteporfin), the first drug treatment for wet AMD.

Read More

Scientific & Medical Advisory Board

Francis Mah, MD

Jay Pepose, MD, PhD

John Sheppard, MD

Russel Van Gelder, MD, PhD

Stephanie Watson, MD

Latest News & Press

View All News
Press Release

Okogen, Inc., Announces Ophthalmology Industry Veteran Joshua Moriarty as New Chief Executive Officer

March 8, 2022
Read More
Press Release

Safe, Effective and Dose Responsive Anti-Viral Activity of OKG-0301 in Patients with Acute Adenoviral Conjunctivitis–Phase 2 Interim Analysis Results from RUBY Clinical Trial

April 29, 2021
Read More
Press Release

Okogen Initiates Phase 2 Clinical Trial (RUBY) of OKG-0301 in Patients

January 31, 2019
Read More

© 2021 Okogen, Inc. All Rights Reserved

United States

Okogen, Inc.
332 Encinitas Blvd. Suite 102
Encinitas, CA 92024, USA

Australia

Okogen Pty Ltd
Level 9, 31 Queen St
Melbourne, VIC 3000 AUS

Main Menu